Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6946 to 6960 of 8907 results

  1. Pancreatic islet cell transplantation (IPG13)

    NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please see NICE's HealthTech guidance 165 for the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE's HealthTech guidance 175 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.

  2. Computed tomographic colonography (virtual colonoscopy) (IPG129)

    We have moved interventional procedures guidance 129 to become HealthTech guidance 78. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  3. Collagen injection for vocal cord augmentation (IPG130)

    We have moved interventional procedures guidance 130 to become HealthTech guidance 79. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  4. Low dose rate brachytherapy for localised prostate cancer (IPG132)

    We have moved interventional procedures guidance 132 to become HealthTech guidance 81. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  5. Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12)

    We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  6. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTE11)

    We have moved health technology evaluation 11 to become HealthTech guidance 695. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  7. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    We have moved health technology evaluation 15 to become HealthTech guidance 701. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  8. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    We have moved health technology evaluation 16 to become HealthTech guidance 712. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  9. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTE13)

    We have moved health technology evaluation 13 to become HealthTech guidance 697. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    We have moved health technology evaluation 14 to become HealthTech guidance 700. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)

    We have moved Health technology evaluation 17 to become HealthTech guidance 713. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  12. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTE18)

    We have moved Health technology evaluation 18 to become HealthTech guidance 718. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. Digital technologies to support self-management of COPD: early value assessment (HTE19)

    We have moved Health technology evaluation 19 to become HealthTech guidance 736. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    We have moved HTE2 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 2 on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.